sorafenib has been researched along with Wasting Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argilés, JM; Busquets, S; López-Soriano, FJ; Penna, F; Toledo, M | 1 |
| Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P | 1 |
1 trial(s) available for sorafenib and Wasting Disease
| Article | Year |
|---|---|
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Wasting Syndrome | 2010 |
1 other study(ies) available for sorafenib and Wasting Disease
| Article | Year |
|---|---|
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Wasting Syndrome | 2014 |